• Vanessa Acquaah (chair)
  
  

• Jennifer McCaffery (lay)

• Charles Ebikeme (lay)

• Thomas Smith (patient)

• Stella O’Brien (patient)

• Jenna Bhimani (clinical)

No conflicts declared by panel

Approved

• The lay summary was well written, providing necessary disease-specific context by clearly explaining how CRC is currently diagnosed and treated. 

• The project supports a clearer understanding of the treatment landscape for CRC patients who face a significant unmet need for improved therapeutic options.

• The aims and objectives were clearly set out, effectively showing BMS’ commitment to improving care for CRC patients through new therapeutics.

• The proposal effectively demonstrated that Real-World Data (RWD) can provide vital insights into current clinical practice and the broader treatment landscape.

• The panel raised several comments on other aspects of the application including:

  • Further clarification on how specific biomarkers (e.g analysing levels of immune cells and sites of metastases) will inform future treatment options for CRC patients.

  • The panel inquired about the methodology that will be used for patient attrition. 

  • The panel noted that it would be beneficial for the researchers to outline how they plan to mitigate any potential study limitations.